Global Antisense & RNAi Therapeutics Market Research Report 2022: Technology, Route, Indication Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F – ResearchAndMarkets.com

Dublin – (work wire) – “Antisense & RNAi Therapeutics Global Market Report 2022: By Technology, By Route, By Invitation” has been added to ResearchAndMarkets.com Show.

The global antisense and RNAI market is expected to grow from $1.32 billion in 2021 to $1.42 billion in 2022, at a compound annual growth rate (CAGR) of 8%. The market is expected to reach $2.14 billion in 2026 with a compound annual growth rate of 10.8%.

The major players in the anti-allergic drug and RNAi market are Alnylam Pharmaceuticals and Benitec Biopharma Ltd. and Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi SA, Acuitas Therapeutics and Antisense Therapeutics Ltd.

The antiallergic and RNAi therapy market consists of sales of antiallergic and RNAi therapeutic products and related services by entities (organizations, individual dealers, and partnerships) that develop antiallergic and RNAi therapies for the treatment of various diseases. RNA-based and RNA-based therapies are advanced methods used to treat various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition, anti-allergic and RNAi therapies find their applications in the treatment of cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

The main techniques of antisense and RNAi therapies are RNA interference, antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both parasite and exogenous pathogenic nucleic acids and regulates protein-coding gene expression.

Various routes of administration include pulmonary delivery, intravenous injection, intradermal injection, intraperitoneal injection, local delivery, and other delivery methods used to indicate oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, else.

The increasing prevalence of coronary artery disease, neurodegenerative disorders and infectious diseases is expected to contribute to the demand for anti-allergic and RNAi therapies market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used to treat various neurodegenerative conditions by repairing mutant genes.

According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases that affect millions of people globally. In the United States, about 930,000 people have developed Parkinson’s disease by the end of 2020. Thus, the increasing prevalence of many neurodegenerative and infectious diseases is expected to lead to the growth of the anti-allergic and RNAi drug market.

The high cost of RNA interference-based drugs is expected to be a major constraint for the growth of antiallergic and RNAi drugs market in the future. For example, according to Future Medicine, Onpattro is about $450,000 a year. Onpattro (patisaran) is an RNA interference-based drug used in the treatment of hereditary amyloidosis-mediated polyneuropathy (hATTR) in adults.

Strict regulations, long product approval process, high development cost, and relatively few patients are few factors that lead to the high cost of RNA interference drugs, which are expected to hamper the growth of antiallergic and RNAi therapies market in the coming years.

Major companies operating in the antisense and RNAi therapy market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to survive in the increasingly competitive market, and companies are developing innovative products as well as exchanging skills and experience with other companies.

While companies have long been collaborating with each other as well as with academic and research institutions in this market by way of partnerships, and in or out of licensing deals, this trend has increased over recent years.

Featured Companies

  • Al-Nilam Pharmaceuticals

  • Benitec Biopharma Ltd.

  • gene signal

  • GlaxoSmithKline Corporation.

  • Eunice Pharmaceuticals

  • Marina Biological Sciences

  • Quark Pharmaceutical Company

  • Sanofi SA

  • Acuitas treatments

  • Antisense Therapeutics Ltd.

  • Arbutus Biopharma (formerly Tekmira Pharmaceuticals)

  • Bio Bath Holdings Company.

  • Kalando Pharmaceuticals

  • Diserna Pharmaceuticals

  • Enzon Pharmaceuticals inc.

  • gradalis

  • iCo . treatments

  • miRagen treatments

  • OLX Pharmaceuticals

  • OncoGeneX Pharmaceuticals

  • Lorus Therapeutics (Aptose Biosciences)

  • Regulus Therapeutics

  • Rexan Pharmaceuticals

  • Rxi . Pharmaceuticals

  • Santaris Pharma A/S (Roche)

  • Sarepta Treatments

  • Silence Therapeutics plc.

  • Sirnaomics Corporation.

  • Tekemira Pharmaceutical Company

  • Cenix BioScience

  • Sirnaomics

Main topics covered:

1. Executive Summary

2. Antisense and RNAi market therapeutic properties

3. Antisense and RNAi Therapeutic Market Trends and Strategies

4. Impact of COVID-19 on anti-allergic and RNAi therapies

5. Antisense & RNAi Therapeutic Market Size and Growth

5.1 Global market for antidepressants and historical RNA therapies, 2016-2021, billion

5.1.1. market drivers

5.1.2. Market Restrictions

5.2 Global Antisense and RNAi Therapy Market Forecast, 2021-2026F, 2031F, billion

5.2.1. market drivers

5.2.2. market restrictions

6. Antiallergic and RNAi Drugs Market Segmentation

6.1 Global Antisense and RNAi Therapeutics Market, Segmentation by Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 Billion

  • RNA interference

  • RNA Antisense

6.2 Global Antisense and RNAi Therapeutics Market, Segmentation by Management Route, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • pulmonary delivery

  • intravenous injection

  • Intradermal injection

  • Intraperitoneal injection

  • spot delivery

  • Other delivery methods

6.3 Global Antisense and RNAi Therapeutics Market, Segmentation by Sign, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 billion

  • Oncology

  • Cardiovascular diseases (CVDs)

  • Respiratory disorders

  • Neurological disorders

  • Infectious diseases

  • else

7. Antisense & RNAi Therapeutic Market Regional and Country Analysis

7.1 Global Antisense and RNAi Therapeutics Market, Segmented by Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 Billion

7.2 Global Antisense and RNAi Therapeutics Market, Segmented by Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $Billion

8. Asia-Pacific Antisense and RNAi Therapy Market

8.1 Asia-Pacific Antisense & RNAi Therapy Market Market Overview

  • Region information, COVID-19 impact, market information, background information, government initiatives, regulations, regulators, major associations, taxes imposed, corporate tax structure, investments, major corporations

8.2 Asia Pacific Antisense & RNAi Therapeutics Market, Segmentation by Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 billion

8.3 Asia Pacific Antisense & RNAi Therapeutics Market, Segmentation by Management Route, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 billion

9. China Antisense & RNAi Therapeutic Market

10. India Antisense & RNAi Therapeutics Market

11. Japan Antisense & RNAi Therapeutic Market

12. Australia Antisense & RNAi Therapeutics Market

13. Indonesia Antisense & RNAi Therapeutics Market

14. South Korea Antisense & RNAi Therapeutics Market

15. Western Europe Antisense & RNAi Therapeutics Market

16. UK Antisense & RNAi Therapeutics Market

17. Germany Antisense and RNAi Therapy Market

18. France Antisense & RNAi Therapeutic Market

19. Eastern Europe Antisense & RNAi Therapeutics Market

20. Russia Antisense and RNAi Therapy Market

21. North American Antisense & RNAi Therapeutics Market

22. USA Antisense & RNAi Therapeutics Market

23. South America Antisense & RNAi Therapeutics Market

24. Brazil Antisense & RNAi Therapeutics Market

25. Middle East Antisense & RNAi Therapeutics Market

26. Africa Antisense & RNAi Therapeutics Market

27. Antisense & RNAi Therapeutics Market Competitive Landscape and Company Profiles

27.1. Antisense & RNAi Therapeutics Market Competitive Landscape

27.2. Antisense and RNAi Therapeutics Market Profiles

28. Antisense and RNAi Therapeutics Pipeline Analysis

29. Major Mergers and Acquisitions in Antisense and RNAi Therapeutics Market

30. Antisense & RNAi Therapeutics Market Outlook and Potential Analysis

For more information on this report, visit https://www.researchandmarkets.com/r/q4hkt1

Leave a Comment